Bond Biosciemces is a privately-held biopharmaceutical company structured around the discovery and development of first-in-class non-absorbed oral therapies that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease. The Companys portfolio is comprised of its lead, BBI-001, in addition to other research stage non-absorbed therapies.
